September 17, 2014
Valeant Pharmaceuticals International Inc. sought a court order Tuesday barring Allergan Inc. from redacting documents on grounds of business strategy in its insider trading suit against Valeant, alleging its takeover target is inventing a federal privilege to justify improperly withholding information.
September 02, 2014
Allergan Inc. hit back on Tuesday against Valeant Pharmaceuticals International Inc.'s allegations Allergan lied to its shareholders about Valeant's financial health amid Valeant's attempted $53 billion hostile takeover, dismissing Valeant's counterclaims as desperate distractions from Allergan's insider trading suit.
August 26, 2014
Allergan Inc. said Tuesday it will hold a special meeting on Dec. 18 where shareholders can vote on a proposed board overhaul, part of a $53 billion takeover bid by Valeant Pharmaceuticals International Inc., and will seek an order blocking Valeant, investor Bill Ackman and Ackman's hedge fund from voting their shares.
August 21, 2014
A California federal judge refused to fast-track Allergan Inc's insider trading suit against Valeant Pharmaceuticals International Inc. as it attempts a hostile takeover of Allergan, ruling Thursday that a special board meeting won't necessarily be put on hold during litigation.
August 20, 2014
Valeant Pharmaceuticals International Inc. and hedge fund Pershing Square Capital Management LP on Tuesday filed counterclaims in Allergan Inc.'s insider trading suit, alleging Allergan, the target of a $53 billion hostile takeover bid, had lied to its own shareholders and solicited Valeant's shareholders to obstruct the takeover.
August 15, 2014
Valeant Pharmaceuticals International Inc. denounced on Thursday Allergan Inc.'s insider trading accusations in a California federal court as a ruse to delay a separate case in Delaware in which Valeant is looking to force Allergan — the target of a hostile $53 billion takeover bid — to call a special shareholders meeting.
August 01, 2014
Allergan Inc. on Friday filed suit against Valeant Pharmaceuticals International Inc., billionaire activist investor Bill Ackman and an Ackman-owned hedge fund, alleging they used inside information to try and make a huge profit at the expense of Allergan shareholders.